{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:00:05Z","timestamp":1790312405692,"version":"4.1.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Hepatoid adenocarcinoma of the stomach (HAS) is a rare, aggressive gastric carcinoma that is frequently associated with elevated alpha-fetoprotein (AFP). We report a patient with resolved hepatitis B virus infection and two spatially distinct gastric lesions: poorly differentiated adenocarcinoma in the gastric body and HAS in the gastric angularis. The disease was initially considered unresectable. After multidisciplinary evaluation, the patient received oxaliplatin, S-1, sintilimab, and apatinib. Treatment produced radiological regression and AFP normalization, enabling total gastrectomy. Histopathology showed no viable carcinoma in either tumor bed or in 20 regional lymph nodes, confirming a pathological complete response. This case illustrates the potential role of individualized conversion therapy in selected patients with alpha-fetoprotein-producing gastric cancer. It does not establish the four-agent regimen as standard care. Interpretation is limited by the single-patient design, short follow-up, absence of lesion-specific sequencing and serial hepatitis B virus DNA data, and a nonstandardized maintenance strategy.<\/jats:p>","DOI":"10.3389\/fonc.2026.1898989","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:27:31Z","timestamp":1790310451000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Conversion therapy with chemotherapy, antiangiogenic therapy, and immunotherapy for locally advanced synchronous gastric hepatoid adenocarcinoma and poorly differentiated adenocarcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Yin","family":"Shu","sequence":"first","affiliation":[{"name":"The Third Clinical Medical College of Xinjiang Medical University, Urumqi","place":["Xinjiang, China"]},{"name":"Department of Gastrointestinal Surgery II, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi","place":["Xinjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyang","family":"Yan","sequence":"additional","affiliation":[{"name":"The Third Clinical Medical College of Xinjiang Medical University, Urumqi","place":["Xinjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paerhati","family":"Shayimu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery II, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi","place":["Xinjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weina","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathological Diagnosis, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi","place":["Xinjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery II, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi","place":["Xinjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Third Clinical Medical College of Xinjiang Medical University, Urumqi","place":["Xinjiang, China"]},{"name":"Department of Gastrointestinal Surgery II, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi","place":["Xinjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00052-2","article-title":"Gastric cancer","volume":"405","author":"Sundar","year":"2025","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13578-025-01424-8","article-title":"Alpha fetoprotein-producing gastric cancer: clinicopathological features and treatment strategies","volume":"15","author":"Luo","year":"2025","journal-title":"Cell Biosci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/6710428","article-title":"Hepatoid adenocarcinoma of stomach: emphasis on the clinical relationship with alpha-fetoprotein-positive gastric cancer","volume":"2019","author":"Chen","year":"2019","journal-title":"BioMed Res Int"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.101004","article-title":"Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer","volume":"14","author":"Li","year":"2021","journal-title":"Transl Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v18.i2.113508","article-title":"Frequency and characteristics of synchronous gastric cancers: need for improved awareness and better detection","volume":"18","author":"Dutta","year":"2026","journal-title":"World J Gastrointest Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.livres.2020.09.004","article-title":"B cell dysfunction in chronic hepatitis B virus infection","volume":"5","author":"Ma","year":"2021","journal-title":"Liver Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/jgh.70177","article-title":"Chronic hepatitis B infection: patient guidance","volume":"41","author":"Mak","year":"2026","journal-title":"J Gastroenterol Hepatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41392-025-02193-z","article-title":"PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastroesophageal junction adenocarcinoma (CAP 06): a multicenter, single-arm, phase 2 trial","volume":"10","author":"Wang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14917","article-title":"Pathological complete remission of liver metastases correlates with elimination of tumor-infiltrating Tregs in gastric cancer","volume":"41","author":"Nakanishi","year":"2021","journal-title":"Anticancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032789","article-title":"New strategy in hemorrhagic gastric cancer: a case report of complete pathological remission after neoadjuvant chemotherapy","volume":"102","author":"Zhou","year":"2023","journal-title":"Med (Baltimore)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-025-02792-4","article-title":"Multidisciplinary treatment for advanced gastric cancer","volume":"30","author":"Kanaji","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-023-01910-x","article-title":"Alpha-fetoprotein-producing gastric cancer with ruptured liver metastasis mimicking hepatocellular carcinoma","volume":"17","author":"Kimura","year":"2024","journal-title":"Clin J Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.11908","article-title":"A unique case of alpha-fetoprotein-negative hepatoid adenocarcinoma of the stomach with associated signet ring cell histological features and linitis plastica","volume":"12","author":"Wichelmann","year":"2020","journal-title":"Cureus"},{"key":"B14","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3892\/ol.2024.14717","article-title":"Alpha-fetoprotein-positive hepatoid adenocarcinoma of the stomach and a new classification: a case report","volume":"28","author":"Ye","year":"2024","journal-title":"Oncol Lett"},{"key":"B15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3892\/ol.2025.14968","article-title":"Synchronous occurrence of primary gastric and liver cancer: a case report","volume":"29","author":"Zhang","year":"2025","journal-title":"Oncol Lett"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn441530-20250328-00129","article-title":"Research advances in immunotherapy for gastric cancer with specific molecular subtypes","volume":"29","author":"Zhou","year":"2026","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1514069","article-title":"Dual-positive gastric cancer: an extremely Malignant subtype of gastric cancer with high serum alpha-fetoprotein and carcinoembryonic antigen concentrations","volume":"14","author":"Xie","year":"2024","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.04.011","article-title":"Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation","volume":"357","author":"Gu","year":"2023","journal-title":"J Control Release"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44309-5","article-title":"Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial","volume":"15","author":"Lin","year":"2024","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02758-x","article-title":"Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial","volume":"30","author":"Verschoor","year":"2024","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-23-2328","article-title":"Low-dose apatinib optimizes vascular normalization and enhances the antitumor effect of PD-1 inhibition in gastric cancer","volume":"13","author":"Tao","year":"2024","journal-title":"Transl Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02850-w","article-title":"Effect of OASL on oxaliplatin-induced immunogenic cell death in gastric cancer via the cGAS-STING signaling pathway","volume":"12","author":"Zhang","year":"2025","journal-title":"Cell Death Discov"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1898989\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:27:33Z","timestamp":1790310453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1898989\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":22,"alternative-id":["10.3389\/fonc.2026.1898989"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1898989","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1898989"}}